Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Leroux Roels, Geert ^a   Maes, Cathy ^a   Clement, Frédéric ^a   van Engelenburg, Frank ^b   van den Dobbelsteen, Marieke ^b   Adler, Michael ^c   Amacker, Mario ^d   Lopalco, Lucia ^e   Bomsel, Morgane ^f   Chalifour, Anick ^g   Fleury, Sylvain ^g  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Kinesis Pharma BV   (Netherlands)

^c CHIMERA BIOTEC GMBH   (Germany)

^d Pevion Biotech Ltd   (Switzerland)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f INSTITUT COCHIN   (France)

^g Mymetics Corporation   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MYM V101 VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIROSOME;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; LOW DRUG DOSE; MUCOSA; NOSE OBSTRUCTION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SKIN REDNESS; SMELLING DISORDER; TRANSCYTOSIS; VACCINATION; VAGINAL SECRETION;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODY SPECIFICITY; FEMALE; HEALTH; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; INJECTIONS, INTRAMUSCULAR; MOLECULAR SEQUENCE DATA; MUCOUS MEMBRANE; PEPTIDE FRAGMENTS; TRANSCYTOSIS; VACCINATION; VACCINES, SUBUNIT; VIROSOMES; YOUNG ADULT;

EID: 84874274760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055438     Document Type: Article

References (108)

1. Shattock RJ, Moore JP, (2003) Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 1: 25-34.
2. Hartley O, Klasse PJ, Sattentau QJ, Moore JP, (2005) V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 21: 171-189.
3. Montero M, van Houten NE, Wang X, Scott1 JK (2008) The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: Dominant site of antibody neutralization and target for vaccine design. Microbiology and molecular biology reviews 72: 54-84.
4. Plotkin SA, Orenstein WA, Offit PA (2008) Vaccines 5th Edition.
5. Mascola JR, Montefiori DC, (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413-444.
6. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868-871.
7. Fuchs JD, Sobieszczyk ME, Hammer SM, Buchbinder SP, (2010) Lessons drawn from recent HIV vaccine efficacy trials. J Acquir Immune Defic Syndr 55Suppl 2: S128-131.
8. IAVI (2010) Database of AIDS vaccine candidate in clinical trials (database online). IAVI Report July 7.
9. Billich A, (2004) AIDSVAX VaxGen. Curr Opin Investig Drugs 5: 214-221.
10. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
11. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433.
12. Mascola JR, (2002) Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20: 1922-1925.
13. Zolla-Pazner S, (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4: 199-210.
14. Bernard NF, Pederson K, Chung F, Ouellet L, Wainberg MA, et al. (1998) HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons. AIDS 12: 2125-2139.
15. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, et al. (2005) Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79: 15547-15555.
16. Pantaleo G, Koup RA, (2004) Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10: 806-810.
17. Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, et al. (1998) Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis 178: 1008-1018.
18. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857-860.
19. Sekaly RP, (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205: 7-12.
20. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
21. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
22. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, et al. (2012) ADCC-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. J Virol.
23. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.
24. Anton PA, Ibarrondo FJ, Boscardin WJ, Zhou Y, Schwartz EJ, et al. (2008) Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments. Vaccine 26: 4617-4623.
25. Pialoux G, Hocini H, Perusat S, Silberman B, Salmon-Ceron D, et al. (2008) Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study. Vaccine 26: 2657-2666.
26. Berneman A, Belec L, Fischetti VA, Bouvet JP, (1998) The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions. Infect Immun 66: 4163-4168.
27. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, et al. (2011) Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34: 269-280.
28. Plotkin SA, (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065.
29. Haase AT, (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
30. Cerutti A, Chen K, Chorny A, (2011) Immunoglobulin responses at the mucosal interface. Annu Rev Immunol 29: 273-293.
31. Mestecky J, Raska M, Novak J, Alexander RC, Moldoveanu Z, (2010) Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design. J Reprod Immunol 85: 81-85.
32. Pavot V, Rochereau N, Genin C, Verrier B, Paul S, (2012) New insights in mucosal vaccine development. Vaccine 30: 142-154.
33. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210.
34. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347.
35. Poignard P, Moldt B, Maloveste K, Campos N, Olson WC, et al. (2012) Protection against High-Dose Highly Pathogenic Mucosal SIV Challenge at Very Low Serum Neutralizing Titers of the Antibody-Like Molecule CD4-IgG2. PLoS One 7: e42209.
36. Broliden K, Hinkula J, Devito C, Kiama P, Kimani J, et al. (2001) Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 79: 29-36.
37. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, et al. (2000) Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 165: 5170-5176.
38. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, et al. (2000) Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 14: 1917-1920.
39. Horton RE, Ball TB, Wachichi C, Jaoko W, Rutherford WJ, et al. (2009) Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res Hum Retroviruses 25: 83-92.
40. Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, et al. (1999) HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13: 23-29.
41. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, et al. (2009) The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 23: 161-175.
42. Clerici M, Barassi C, Devito C, Pastori C, Piconi S, et al. (2002) Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 16: 1731-1741.
43. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, et al. (2002) Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 30: 413-420.
44. Pastori C, Barassi C, Piconi S, Longhi R, Villa ML, et al. (2000) HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. J Biol Regul Homeost Agents 14: 15-21.
45. Choi RY, Levinson P, Guthrie BL, Lohman-Payne B, Bosire R, et al. (2012) Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS 26: 2155-2163.
46. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412.
47. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84: 1302-1313.
48. Guenaga J, Wyatt RT, (2012) Structure-guided Alterations of the gp41-directed HIV-1 Broadly Neutralizing Antibody 2F5 Reveal New Properties Regarding its Neutralizing Function. PLoS Pathog 8: e1002806.
49. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642-6647.
50. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17: 1757-1765.
51. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, et al. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79: 1252-1261.
52. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905.
53. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, et al. (2009) HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2: 412-426.
54. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, et al. (2003) The HIV Env-mediated fusion reaction. Biochim Biophys Acta 1614: 36-50.
55. Alfsen A, Bomsel M, (2002) HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem 277: 25649-25659.
56. Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, et al. (2007) Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines 6: 711-721.
57. Moser C, Amacker M, Zurbriggen R, (2011) Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 10: 437-446.
58. Wilschut J, (2009) Influenza vaccines: the virosome concept. Immunol Lett 122: 118-121.
59. Coutant J, Yu H, Clement MJ, Alfsen A, Toma F, et al. (2008) Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J 22: 4338-4351.
60. Tamura M, Webster RG, Ennis FA, (1991) Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology 182: 211-219.
61. Tamura M, Webster RG, Ennis FA, (1994) Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J Virol 68: 3499-3504.
62. Herzog C, Hartmann K, Kunzi V, Kursteiner O, Mischler R, et al. (2009) Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 27: 4381-4387.
63. Zuccotti G, Amendola A, Vigano A, Pariani E, Zappa A, et al. (2007) Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine 25: 6692-6698.
64. Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, et al. (2010) Targeting Trojan Horse leukocytes for HIV prevention. AIDS 24: 163-187.
65. UNAIDS (2012) Global report: UNAIDS report on the global AIDS epidemic. 1-110.
66. Mischler R, Metcalfe IC, (2002) Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 20Suppl 5: B17-23.
67. Hildesheim A, McShane LM, Schiffman M, Bratti MC, Rodriguez AC, et al. (1999) Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. J Immunol Methods 225: 131-143.
68. Kozlowski PA, Lynch RM, Patterson RR, Cu-Uvin S, Flanigan TP, et al. (2000) Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 24: 297-309.
69. Adler M, Wacker R, Niemeyer CM, (2003) A real-time immuno-PCR assay for routine ultrasensitive quantification of proteins. Biochem Biophys Res Commun 308: 240-250.
70. Adler M, Wacker R, Niemeyer CM, (2008) Sensitivity by combination: immuno-PCR and related technologies. Analyst 133: 702-718.
71. Niemeyer CM, Adler M, Wacker R, (2007) Detecting antigens by quantitative immuno-PCR. Nat Protoc 2: 1918-1930.
72. Sano T, Smith CL, Cantor CR, (1992) Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. Science 258: 120-122.
73. Frey A, Di Canzio J, Zurakowski D, (1998) A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 221: 35-41.
74. Maecker HT, (2009) Multiparameter flow cytometry monitoring of T cell responses. Methods Mol Biol 485: 375-391.
75. Donadoni C, Bisighini C, Scotti L, Diomede L, Ngyen M, et al. (2010) Setting of methods for analysis of mucosal antibodies in seminal and vaginal fluids of HIV seropositive subjects from Cambodian and Italian cohorts. PLoS One 5: e9920.
76. Mestecky J, Wright PF, Lopalco L, Staats HF, Kozlowski PA, et al. (2011) Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses 27: 469-486.
77. Diomede L, Nyoka S, Pastori C, Scotti L, Zambon A, et al. (2012) Passively transmitted gp41 antibodies in babies born from subtype C HIV-1 seropositive women: correlation between fine specificity and protection. J Virol.
78. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
79. Alfsen A, Iniguez P, Bouguyon E, Bomsel M, (2001) Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 166: 6257-6265.
80. Hocini H, Belec L, Iscaki S, Garin B, Pillot J, et al. (1997) High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses 13: 1179-1185.
81. Hocini H, Bomsel M, (1999) Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. J Infect Dis 179Suppl 3: S448-453.
82. Johansson EL, Wassen L, Holmgren J, Jertborn M, Rudin A, (2001) Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 69: 7481-7486.
83. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP, (1997) Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 65: 1387-1394.
84. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, et al. (2002) Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 169: 566-574.
85. Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, et al. (2011) Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS One 6: e25165.
86. Ansari AA, (2004) Autoimmunity, anergy, lentiviral immunity and disease. Autoimmun Rev 3: 530-540.
87. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
88. Silvestris F, Williams RC Jr, Dammacco F, (1995) Autoreactivity in HIV-1 infection: the role of molecular mimicry. Clin Immunol Immunopathol 75: 197-205.
89. Chen K, Cerutti A, (2010) Vaccination strategies to promote mucosal antibody responses. Immunity 33: 479-491.
90. Kunkel EJ, Butcher EC, (2003) Plasma-cell homing. Nat Rev Immunol 3: 822-829.
91. Kunkel EJ, Kim CH, Lazarus NH, Vierra MA, Soler D, et al. (2003) CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest 111: 1001-1010.
92. Tudor D, Yu H, Maupetit J, Drillet AS, Bouceba T, et al. (2012) Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A.
93. Anderson DJ, Politch JA, Tucker LD, Fichorova R, Haimovici F, et al. (1998) Quantitation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission. AIDS Res Hum Retroviruses 14Suppl 1: S43-49.
94. Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, et al. (2007) Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 21: 1723-1730.
95. Anderson D, Politch JA, Pudney J, (2011) HIV infection and immune defense of the penis. Am J Reprod Immunol 65: 220-229.
96. Pudney J, Anderson D, (2011) Innate and acquired immunity in the human penile urethra. J Reprod Immunol 88: 219-227.
97. Rothaeusler K, Ma ZM, Qureshi H, Carroll TD, Rourke T, et al. (2012) Antiviral antibodies and T cells are present in the foreskin of simian immunodeficiency virus-infected rhesus macaques. J Virol 86: 7098-7106.
98. Peduzzi E, Westerfeld N, Zurbriggen R, Pluschke G, Daubenberger CA, (2008) Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clin Immunol 127: 188-197.
99. Schroeder HW Jr, Cavacini L, (2010) Structure and function of immunoglobulins. J Allergy Clin Immunol 125: S41-52.
100. Yu Q, Yu R, Qin X, (2010) The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol 7: 334-340.
101. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, et al. (2011) A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366: 8-19.
102. Dugast AS, Tonelli A, Berger CT, Ackerman ME, Sciaranghella G, et al. (2011) Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 415: 160-167.
103. Bakema JE, van Egmond M, (2011) The human immunoglobulin A Fc receptor FcalphaRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol 4: 612-624.
104. Duval M, Posner MR, Cavacini LA, (2008) A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J Virol 82: 4671-4674.
105. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, et al. (2006) Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 80: 6177-6181.
106. Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, et al. (2005) Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 174: 5472-5480.
107. van Spriel AB, van den Herik-Oudijk IE, van Sorge NM, Vile HA, van Strijp JA, et al. (1999) Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils. J Infect Dis 179: 661-669.
108. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J, (2012) HIV-Specific Antibodies Capable of ADCC Are Common in Breastmilk and Are Associated with Reduced Risk of Transmission in Women with High Viral Loads. PLoS Pathog 8: e1002739.